Tyrphostin AG 494 is primarily used in research settings as a selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase. It is widely applied in studies to investigate the role of EGFR signaling in various cellular processes, including cell proliferation, differentiation, and survival. Researchers use it to explore its potential in inhibiting cancer cell growth, particularly in tumors that overexpress EGFR. Additionally, it is employed in experiments to understand the molecular mechanisms underlying EGFR-related diseases and to develop targeted therapeutic strategies. Its application extends to studying the effects of EGFR inhibition on inflammation and wound healing processes.